NCT06545942 is a Phase 1 clinical trial of MOMA-313 in Advanced Solid Tumor, sponsored by MOMA Therapeutics.

Who is sponsoring NCT06545942?

NCT06545942 is sponsored by MOMA Therapeutics.

What drugs are being tested in NCT06545942?

Interventions in NCT06545942: MOMA-313, Olaparib.

What condition does NCT06545942 study?

NCT06545942 studies Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency.

Is NCT06545942 still recruiting?

NCT06545942 is currently active, enrolled. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT06545942

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Active, enrolled Phase 1 Last updated 17 April 2026

What this trial tests

Phase 1 trial testing MOMA-313 in Advanced Solid Tumor in 220 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 August 2024

Primary endpoint
31 May 2027

30 November 2027

Quick facts

Lead sponsor	MOMA Therapeutics
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	220
Start date	13 August 2024
Primary completion	31 May 2027
Estimated completion	30 November 2027
Sites	18 locations across United Kingdom, United States, Spain

Drugs / interventions tested

MOMA-313 — full drug profile →
Olaparib (olaparib) — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Metastatic Solid Tumor — all drugs for Metastatic Solid Tumor →
Prostate Cancer — all drugs for Prostate Cancer →
Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

MOMA Therapeutics — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor or Metastatic Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

DNA repair and the contribution to chemotherapy resistance.
Nesic K, Parker P, Swisher EM, Krais JJ. · · 2025 · cited 16× · PMID 40420317 · DOI 10.1186/s13073-025-01488-8
Structural Chemistry of Helicase Inhibition.
Selvaratnam L, Willson TM, Schapira M. · · 2025 · cited 14× · PMID 39933052 · DOI 10.1021/acs.jmedchem.4c01909
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2
BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?
Zekavat L, Jain A. · · 2025 · PMID 41009605 · DOI 10.3390/ijms26189041

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06545942 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MOMA Therapeutics
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06545942.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing